Company Analysis
Sign in

Geron Corporation (GERN)

Nasdaq: GERN · Pharmaceutical Preparations · Foster City, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade3.5
◀ Past 4.3● Present 3.5▶ Future 3.1
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

206 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Geron Corporation’s names, not what it holds today.

Patents granted
206
206 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 3 in 2024 and 1 in 2023
Applications published
117
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
Organic fine chemistry5
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Geron Corporation its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
206 granted
48 published
Geron Corporation its own name
named as the applicant on its applications, in US
0 granted
69 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,442,000Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasmsPharmaceuticalsGeron Corporation
Aug 26, 202512,398,162Guanine analogs as telomerase substrates and telomere length affectorsPharmaceuticalsGeron Corporation
Aug 19, 202512,391,946Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasmsPharmaceuticalsGeron Corporation
Apr 1, 202512,264,174Process for preparing imetelstatOrganic fine chemistryGeron Corporation
Jan 21, 202512,201,645Methods of treating myelodysplastic syndromePharmaceuticalsGeron Corporation
Dec 24, 202412,171,778Methods of treating myelodysplastic syndromePharmaceuticalsGeron Corporation
Oct 22, 202412,122,735Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1- (protected hydroxy)-propane salts and methods of making the sameOrganic fine chemistryGeron Corporation
May 21, 202411,987,540Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the sameOrganic fine chemistryGeron Corporation
Aug 29, 202311,739,114Oligonucleotide compositions and methods of making the sameBiotechnologyGeron Corporation
Dec 20, 202211,530,179Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the sameOrganic fine chemistryGeron Corporation
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 26, 20252025/0207136Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative NeoplasmsPharmaceuticalsGeron Corporation · patent 12,442,000 granted from it
May 29, 20252025/0170160Methods of Treating Myelodysplastic SyndromePharmaceuticalsGeron Corporation
Jan 9, 20252025/0011359OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAMEBiotechnologyGeron Corporation
Oct 31, 20242024/0360074Crystalline Solids of 3-Palmitoyl-Amido-1,2-Propanediol and 3-Palmitoyl-Amido-2-Hydroxy-1-Dimethoxytriphenylmethylether-Propane and Methods of Making and Using the SameOrganic fine chemistryGeron Corporation
Oct 17, 20242024/0343713TELOMERASE INHIBITOR COMPOUNDSOrganic fine chemistryGeron Corporation
Sep 26, 20242024/0318232Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyBiotechnologyGeron Corporation
Sep 12, 20242024/0300992Synthesis of Protected 3'-amino Nucleoside MonomersOrganic fine chemistryGeron Corporation
Aug 29, 20242024/0285773METHODS OF TREATING MYELODYSPLASTIC SYNDROME AND MONITORING THE TREATMENTPharmaceuticalsGeron Corporation
Aug 8, 20242024/0262854Process for Preparing ImetelstatOrganic fine chemistryGeron Corporation · patent 12,264,174 granted from it
Jun 20, 20242024/0199672Process for Preparing ImetelstatOrganic fine chemistryGeron Corporation
What it applied for, 2024 to 2025: Organic fine chemistry 6 · Biotechnology 3 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton GERN · research, not advice